### Learner Notification

**MED Learning Group**

**The New BTKids on the Block: Compelling Rationale for Non-Covalent Bruton Tyrosine Kinase Inhibition in B-cell Cancers**

**Various Dates: May 30 – December 11, 2023**

**Online**

**Acknowledgement of Financial Commercial Support**

Lilly

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Review the developing resistance and challenges to tolerability associated with BTK Inhibition in patients with B-cell malignancies.
2. Optimally sequence therapy in those patients who develop resistance to or are refractory to B-cell malignancy.
3. Evaluate the findings of late-stage BTK Inhibitor clinical trials with relapsed/ refractory B-cell malignancies.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Matthew S. | Davids | UpToDate: Royalties, AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals: Consultant, Novartis: Contracted Research, Aptitude Health, Bioascend, Curio Science, Research to Practice: Other |
| Millena | De Brito | NA |
| Barbara | Eichhorst | AbbVie, AstraZeneca, BeiGene, Lilly, Kite: Consultant, Roche, AbbVie, BeiGene, AstraZeneca, MSD, Kite: Speakers Bureau, Janssen, Gilead, Roche, AbbVie, BeiGene, AstraZeneca: contracted Research |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Deb | Gordon | NA |
| Amanda | Jenkins | NA |
| Melissa A. | Johnson | NA |
| Aimee | Meissner | NA |
| Shazia | Nakhoda | BTG/SERB: Contracted Research, ADC Therapeutics, Bristol Myers-Squibb, BTG/SERB: Consultant |
| Lydia | Scarfò | AbbVie, AstraZeneca, BeiGene, Janssen, Lilly: Consultant, Octapharma: Speakers Bureau |
| Jo | Shultz | NA |
| Lauren | Welch | NA |
| Jennifer A. | Woyach | Pharmacyclics, Janssen, AstraZeneca, Arqule, Abbvie, Beigene, Loxo, Newave, Genetech: Consultant, Abbvie, Loxo, Verastem, Karyopharm, Morphosys, Schrodinger, Mingsight: Contracted Research |

Questions? Email Certificate@AmedcoEmail.com